argenx Crecimiento futuro

Future controles de criterios 6/6

Se prevé un crecimiento anual de los beneficios y los ingresos de argenx de 55.3% y 25.1% por año respectivamente. Se prevé que el BPA crezca en un 57.5% al año. Se espera que la rentabilidad financiera sea de 20.4% en 3 años.

Información clave

55.3%

Tasa de crecimiento de los beneficios

57.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	43.0%
Tasa de crecimiento de los ingresos	25.1%
Rentabilidad financiera futura	20.4%
Cobertura de analistas	Good
Última actualización	21 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Results: argenx SE Confounded Analyst Expectations With A Surprise Profit

Jul 29

Recent updates

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Mar 24

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Mar 05

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

Feb 23

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Dec 18

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

Jul 28

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Jul 17

Revenues Tell The Story For argenx SE (EBR:ARGX)

Jun 20

argenx (EBR:ARGX) Is Using Debt Safely

May 08

We Think argenx (EBR:ARGX) Can Afford To Drive Business Growth

Apr 20

Previsiones de crecimiento de beneficios e ingresos

ENXTBR:ARGX - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3,939	1,153	969	N/A	24
12/31/2025	3,051	541	256	N/A	29
12/31/2024	2,067	91	-350	N/A	29
9/30/2024	1,909	-40	N/A	N/A	N/A
6/30/2024	1,660	-204	-325	-260	N/A
3/31/2024	1,451	-328	N/A	N/A	N/A
12/31/2023	1,269	-295	-464	-420	N/A
9/30/2023	1,029	-234	N/A	N/A	N/A
6/30/2023	835	-397	-758	-654	N/A
3/31/2023	639	-511	N/A	N/A	N/A
12/31/2022	441	-710	-967	-863	N/A
9/30/2022	286	-909	N/A	N/A	N/A
6/30/2022	146	-907	-874	-876	N/A
3/31/2022	381	-595	N/A	N/A	N/A
12/31/2021	528	-408	-728	-607	N/A
9/30/2021	510	-373	N/A	N/A	N/A
6/30/2021	526	-319	-601	-474	N/A
3/31/2021	206	-573	N/A	N/A	N/A
12/31/2020	62	-608	-404	-398	N/A
9/30/2020	75	-535	N/A	N/A	N/A
6/30/2020	70	-359	-263	-255	N/A
3/31/2020	73	-275	N/A	N/A	N/A
12/31/2019	93	-181	105	152	N/A
9/30/2019	72	-109	N/A	N/A	N/A
6/30/2019	68	-104	188	230	N/A
3/31/2019	70	-47	N/A	N/A	N/A
12/31/2018	33	-76	-62	-62	N/A
9/30/2018	41	-56	N/A	N/A	N/A
6/30/2018	44	-47	N/A	-57	N/A
3/31/2018	50	-46	N/A	N/A	N/A
12/31/2017	49	-34	N/A	-44	N/A
9/30/2017	42	-30	N/A	N/A	N/A
6/30/2017	39	-25	N/A	-31	N/A
3/31/2017	23	-29	N/A	N/A	N/A
12/31/2016	18	-22	N/A	11	N/A
9/30/2016	17	-20	N/A	N/A	N/A
6/30/2016	14	-17	N/A	16	N/A
3/31/2016	12	-17	N/A	N/A	N/A
12/31/2015	11	-17	N/A	-15	N/A
9/30/2015	10	-16	N/A	N/A	N/A
6/30/2015	9	-14	N/A	-10	N/A
3/31/2015	7	-12	N/A	N/A	N/A
12/31/2014	7	-12	N/A	-6	N/A
9/30/2014	6	-10	N/A	N/A	N/A
6/30/2014	7	-8	N/A	-6	N/A
3/31/2014	7	-9	N/A	-8	N/A
12/31/2013	7	-8	N/A	-9	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ARGX sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (1.4%).

Beneficios vs. Mercado: Se prevé que ARGX sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ARGX sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (25.1% al año) de ARGX crezcan más rápidamente que los del mercado Belgian (7.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (25.1% al año) de ARGX crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ARGX sea alta dentro de 3 años (20.4%)

argenx Crecimiento futuro

Future controles de criterios 6/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2024

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Results: argenx SE Confounded Analyst Expectations With A Surprise Profit

Forecast to breakeven in 2025

Consensus EPS estimates fall by 12%, revenue upgraded

Recent updates

New minor risk - Shareholder dilution

Argenx Se Advances Clinical Development of Efgartigimod Sc in Idiopathic Inflammatory Myopathies

Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China

Investor Optimism Abounds argenx SE (EBR:ARGX) But Growth Is Lacking

Second quarter 2024 earnings released: EPS: US$0.49 (vs US$1.69 loss in 2Q 2023)

Forecast to breakeven in 2024

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Argenx Announces Publication in the Lancet Neurology of Pivotal Adhere Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

Is argenx SE (EBR:ARGX) Trading At A 45% Discount?

Independent Non-Executive Director recently sold €1.9m worth of stock

Results: argenx SE Confounded Analyst Expectations With A Surprise Profit

Forecast to breakeven in 2025

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

argenx SE to Report Fiscal Year 2024 Results on Feb 27, 2025

Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

argenx SE's (EBR:ARGX) Shares Climb 26% But Its Business Is Yet to Catch Up

argenx SE Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Consensus EPS estimates fall by 12%, revenue upgraded

First quarter 2024 earnings released: US$1.04 loss per share (vs US$0.52 loss in 1Q 2023)

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE's (EBR:ARGX) CEO Looks Like They Deserve Their Pay Packet

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Investors Appear Satisfied With argenx SE's (EBR:ARGX) Prospects

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Analyst Estimates: Here's What Brokers Think Of argenx SE (EBR:ARGX) After Its Yearly Report

Consensus EPS estimates upgraded to US$1.43 loss

Consensus estimates of losses per share improve by 13%

Analysts Have Made A Financial Statement On argenx SE's (EBR:ARGX) Full-Year Report

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

argenx SE (EBR:ARGX) Shares Could Be 24% Below Their Intrinsic Value Estimate

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE, Annual General Meeting, May 07, 2024

CEO & Executive Director recently sold €1.0m worth of stock

Price target decreased by 11% to €459

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Getting In Cheap On argenx SE (EBR:ARGX) Is Unlikely

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Consensus EPS estimates upgraded to US$4.76 loss, revenue downgraded

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

Consensus EPS estimates fall by 17%

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 16%

Consensus EPS estimates fall by 19%

Independent Chairman of the Board recently sold €3.8m worth of stock

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

CEO & Executive Director exercised options to buy €36m worth of stock.

CEO & Executive Director recently sold €1.9m worth of stock

Independent Non-Executive Director exercised options and sold €3.3m worth of stock

Consensus EPS estimates upgraded to US$4.71 loss

Consensus revenue estimates increase by 10%

Price target increased by 8.0% to €491

Broker Revenue Forecasts For argenx SE (EBR:ARGX) Are Surging Higher

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

New minor risk - Shareholder dilution

Price target increased by 9.4% to €476

New major risk - Share price stability

Consensus EPS estimates upgraded to US$5.73 loss

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Forecast to breakeven in 2025

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

An Intrinsic Calculation For argenx SE (EBR:ARGX) Suggests It's 31% Undervalued

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis